~~<i id='1743F1E0B7'><strike id='1743F1E0B7'><tt id='1743F1E0B7'><pre id='1743F1E0B7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

hotspot

author：focus 2025-09-27 15:19:50 - browse：14883

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Biotech investment managers search for lucrative opportunities

explore

focus

entertainment

Catherine,ThePrincessofWalesannouncesinaMarch22videomessagethatsheisreceivingapreventativecourseofch

WSS

Chinese researcher claims birth of first gene

This gene therapy has record $4.25 million price. It's saved children.

Texas board proposes rules on abortion law emergency exemption

EF3 tornado rips through North Carolina amid extreme weather nationwide

7 more heat

Tesla recalling nearly 16,000 of its 2021

knowledge

hotspot

explore

After affirmative action ruling, medical educators look to 'holistic review'

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Bright Health sells Medicare Advantage business to Molina

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Hepatitis C has a cure — but many Americans still lack access to it

Why Congress must ban federal programs from using QALYs

Affirmative action in medical school literally saved lives

Yancopoulos of Regeneron works to expand Dupixent success

Wildfire smoke exposes gaps in outdoor worker protections

Medicare Advantage insurers pressure Biden for bigger payments

focus

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Texas Department of Public Safety speaks out on migrant abuse allegations

Why Congress must ban federal programs from using QALYs

I learned firsthand about improving diversity in clinical trials

Stanford president's case begs question: Who takes blame?

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

entertainment

entertainment

entertainment

entertainment